adherent cell line  (ATCC)

Journal: Biomolecules & Therapeutics

Article Title: RBM15-Mediated m6A Modification Regulates Proliferation and Migration of Pancreatic Cancer Cells via the lncRNA LINC01320/miR-1287-5p/FBXO11 Axis

doi: 10.4062/biomolther.2025.159

Figure Lengend Snippet: RBM15 knockdown inhibits proliferation, invasion, and migration of PC cells. RBM15 siRNAs (si-RBM15#1,2,3) were transfected into SW1990 and BxPC-3 cells, with si-NC as a control. (A) RT-qPCR to detect the mRNA level of RBM15; si-RBM15#3 with better transfection efficiency was selected for subsequent detection. (B) Western blot to detect the protein expression of RBM15 in cells. (C, D) CCK-8 assay to detect cell proliferation. (E) Clone formation assay to detect cell proliferation. (F) Transwell assay to detect cell invasion and migration. Three biological replicate assays were performed in cells, and data were expressed as mean ± standard deviation. Two-way ANOVA was used to compare data between multiple groups, followed by Tukey’s post hoc test. (A) ** p <0.01 vs. si-NC; others: ** p <0.01.

Article Snippet: PC cell lines Panc 03.27 (CRL-2549; RRID:CVCL_1635), SW1990 (CRL-2172; RRID:CVCL_1723), BxPc3 (CRL-1687; RRID:CVCL_XX78), and MIA PaCa-2 (CRM-CRL-1420; RRID:CVCL_0428) and normal immortalized human pancreatic epithelial cell line HPDE6C7 (CRL-4023; RRID:CVCL_0P38) purchased from ATCC were cultured in DMEM (Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) and 1% penicillin and streptomycin (Gibco, Grand Island, NY, USA) in an incubator (ThermoFisher, Waltham, MA, USA) at 37°C and 5% CO 2 .

Techniques: Knockdown, Migration, Transfection, Control, Quantitative RT-PCR, Western Blot, Expressing, CCK-8 Assay, Tube Formation Assay, Transwell Assay, Standard Deviation

Journal: bioRxiv

Article Title: Metabolic and Anti-Proliferative Responses of Pancreatic Cancer Cells to Ultrasound and Nanobubble Treatment

doi: 10.64898/2026.04.24.720507

Figure Lengend Snippet: Passive cavitation detection spectrograms recorded during US exposure of pancreatic cancer cells treated with NBs. US was applied either immediately after NB addition (t = 0, extracellular NBs present) or after a 1-hour incubation followed by washing to remove extracellular NBs (1 h wash). Spectrograms show acoustic emissions for PANC-1 and BxPC-3 cells under both conditions. Immediate US exposure produced stronger broadband and harmonic emissions, whereas delayed US after washing resulted in reduced acoustic signal intensity, indicating reduced cavitation activity when extracellular NBs were removed and primarily cell-associated NBs remained (Supplemental Video1)

Article Snippet: BxPC-3 cells (ATCC CRL-1687) were maintained in RPMI 1640 (GibcoTM, Thermo Fisher Scientific, Milano, cat# 11875093) supplemented with 10% (v/v) FCS (GibcoTM, Thermo Fisher Scientific, Milano, cat# 10437-036) under identical incubation conditions.

Techniques: Incubation, Produced, Activity Assay

Journal: bioRxiv

Article Title: Metabolic and Anti-Proliferative Responses of Pancreatic Cancer Cells to Ultrasound and Nanobubble Treatment

doi: 10.64898/2026.04.24.720507

Figure Lengend Snippet: Cell viability measured using trypan blue exclusion in BxPC-3 and PANC-1 cells at 1 hour and 24 hours after treatment. Treatment groups included untreated control, US only, US applied immediately after NB addition (NB + US t = 0), US applied after 1-hour NB incubation followed by washing (NB 1 h + US), and NBs only (NB 1 h). Immediate US exposure in the presence of extracellular NBs resulted in a greater reduction in viability compared with delayed US exposure after washing. Viability differences were more pronounced at 24 hours than at 1 hour, indicating delayed treatment effects. Data are presented as percent viability relative to untreated control. Statistical significance is indicated, n=8, (*) P < 0.05, (**) P < 0.01.

Article Snippet: BxPC-3 cells (ATCC CRL-1687) were maintained in RPMI 1640 (GibcoTM, Thermo Fisher Scientific, Milano, cat# 11875093) supplemented with 10% (v/v) FCS (GibcoTM, Thermo Fisher Scientific, Milano, cat# 10437-036) under identical incubation conditions.

Techniques: Control, Incubation

Journal: bioRxiv

Article Title: Metabolic and Anti-Proliferative Responses of Pancreatic Cancer Cells to Ultrasound and Nanobubble Treatment

doi: 10.64898/2026.04.24.720507

Figure Lengend Snippet: (a) Representative immunofluorescence images of BxPC-3 cells stained for Ki-67 (proliferation marker) and nuclei (DAPI) under different treatment conditions: untreated, US only, US applied immediately after NB addition (NB + US 0T), US applied after 1-hour NB incubation and washing (NB + US 1T), and NBs only. (b) Quantification of the percentage of Ki-67 positive proliferating cells for each treatment group. US combined with NBs significantly reduced proliferative activity compared with controls, with the greatest reduction observed when US was applied immediately after NB addition. Data are presented as mean ± SD with statistical significance indicated. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001.

Article Snippet: BxPC-3 cells (ATCC CRL-1687) were maintained in RPMI 1640 (GibcoTM, Thermo Fisher Scientific, Milano, cat# 11875093) supplemented with 10% (v/v) FCS (GibcoTM, Thermo Fisher Scientific, Milano, cat# 10437-036) under identical incubation conditions.

Techniques: Immunofluorescence, Staining, Marker, Incubation, Activity Assay

Journal: bioRxiv

Article Title: Metabolic and Anti-Proliferative Responses of Pancreatic Cancer Cells to Ultrasound and Nanobubble Treatment

doi: 10.64898/2026.04.24.720507

Figure Lengend Snippet: (a-b) Optical density measurements over 72 hours representing metabolic activity measured using the MTT assay in BxPC-3 (a) and PANC-1 (b) cells following treatment. (c-d) Extracellular acidification rate (ECAR) measurements over time for BxPC-3 (c) and PANC-1 (d) cells, indicating glycolytic activity. (e-f) Oxygen consumption rate (OCR) measurements over time for BxPC-3 (e) and PANC-1 (f) cells, indicating mitochondrial respiration. Treatment groups included untreated control, US only, US applied immediately after NB addition, US applied after 1-hour NB incubation and washing, and NBs only. The data demonstrate intrinsic metabolic differences between cell lines and timing-dependent metabolic responses to US-NB treatments. Data were analyzed using GraphPad Prism 8. Mean ± SD is reported with two-way ANOVA with Tukey’s (*) P < 0.05, (**) P < 0.01, (***) P < 0.001, (****) P < 0.0001.

Article Snippet: BxPC-3 cells (ATCC CRL-1687) were maintained in RPMI 1640 (GibcoTM, Thermo Fisher Scientific, Milano, cat# 11875093) supplemented with 10% (v/v) FCS (GibcoTM, Thermo Fisher Scientific, Milano, cat# 10437-036) under identical incubation conditions.

Techniques: Activity Assay, MTT Assay, Control, Incubation

Journal: Cell Reports Medicine

Article Title: A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer

doi: 10.1016/j.xcrm.2026.102688

Figure Lengend Snippet:

Article Snippet: BxPC-3 , ATCC , CRL-1687TM.

Techniques: Recombinant, Virus, Microarray, Labeling, CCK-8 Assay, Expressing, Plasmid Preparation, Luciferase, Software